Clinical Outcome with Standard Regimen Plus Clofazimine or Moxifloxacin in Cavitary Mycobacterium Avium Complex Pulmonary Disease

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2022 Nov 3

PMID 36326247

Authors

Yea Eun Park

Yong Pil Chong

Hyun Joo Lee

Tae Sun Shim

Kyung-Wook Jo

Affiliations

Soon will be listed here.

Abstract

In this retrospective analysis including 173 patients in a tertiary referral center in South Korea, compared with the standard therapeutic regimen, clofazimine or moxifloxacin plus standard treatment regimen potentially did not induce a higher 1-year culture conversion rate in patients with Mycobacterium avium complex pulmonary disease who present with cavitary lesions (fibrocavitary or cavitary nodular bronchiectatic type).

Citing Articles

Drugs for treating infections caused by non-tubercular mycobacteria: a narrative review from the study group on mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine.

Calcagno A, Coppola N, Sarmati L, Tadolini M, Parrella R, Matteelli A Infection. 2024; 52(3):737-765.

PMID: 38329686 PMC: 11142973. DOI: 10.1007/s15010-024-02183-3.

References

Koh W, Hong G, Kim S, Jeong B, Park H, Jeon K . Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen. Antimicrob Agents Chemother. 2013; 57(5):2281-5. PMC: 3632919. DOI: 10.1128/AAC.02281-12. View

Martiniano S, Wagner B, Levin A, Nick J, Sagel S, Daley C . Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection. Chest. 2017; 152(4):800-809. DOI: 10.1016/j.chest.2017.04.175. View

Daley C, Iaccarino J, Lange C, Cambau E, Wallace Jr R, Andrejak C . Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J. 2020; 56(1). PMC: 8375621. DOI: 10.1183/13993003.00535-2020. View

Koh W, Moon S, Kim S, Woo M, Kim S, Jhun B . Outcomes of complex lung disease based on clinical phenotype. Eur Respir J. 2017; 50(3). DOI: 10.1183/13993003.02503-2016. View

Zweijpfenning S, Kops S, Boeree M, Kuipers S, van Ingen J, Hoefsloot W . Treatment of severe complex pulmonary disease with adjunctive amikacin and clofazimine standard regimen alone: a retrospective study. ERJ Open Res. 2021; 7(4). PMC: 8607114. DOI: 10.1183/23120541.00466-2021. View

Griffith D, Aksamit T . Managing Mycobacterium avium Complex Lung Disease With a Little Help From My Friend. Chest. 2020; 159(4):1372-1381. DOI: 10.1016/j.chest.2020.10.031. View

Dheda K, Lenders L, Magombedze G, Srivastava S, Raj P, Arning E . Drug-Penetration Gradients Associated with Acquired Drug Resistance in Patients with Tuberculosis. Am J Respir Crit Care Med. 2018; 198(9):1208-1219. PMC: 6221573. DOI: 10.1164/rccm.201711-2333OC. View

Kwak N, Whang J, Yang J, Kim T, Kim S, Yim J . Minimal Inhibitory Concentration of Clofazimine Among Clinical Isolates of Nontuberculous Mycobacteria and Its Impact on Treatment Outcome. Chest. 2020; 159(2):517-523. DOI: 10.1016/j.chest.2020.07.040. View

Asakura T, Suzuki S, Fukano H, Okamori S, Kusumoto T, Uwamino Y . Sitafloxacin-Containing Regimen for the Treatment of Refractory Complex Lung Disease. Open Forum Infect Dis. 2019; 6(4):ofz108. PMC: 6519390. DOI: 10.1093/ofid/ofz108. View

10.

Lee J, Park Y, Chong Y, Shim T, Jo K . Efficacy of Fluoroquinolones as Substitutes for Ethambutol or Rifampin in the Treatment of Mycobacterium avium Complex Pulmonary Disease According to Radiologic Types. Antimicrob Agents Chemother. 2021; 66(2):e0152221. PMC: 8846399. DOI: 10.1128/AAC.01522-21. View

11.

Boyle D, Zembower T, Qi C . Relapse versus Reinfection of Mycobacterium avium Complex Pulmonary Disease. Patient Characteristics and Macrolide Susceptibility. Ann Am Thorac Soc. 2016; 13(11):1956-1961. DOI: 10.1513/AnnalsATS.201605-344BC. View

12.

Haworth C, Banks J, Capstick T, Fisher A, Gorsuch T, Laurenson I . British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017; 72(Suppl 2):ii1-ii64. DOI: 10.1136/thoraxjnl-2017-210927. View